{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"118.48","value":"579.49"},{"groupId":"OG001","spread":"164.84","value":"663.00"},{"groupId":"OG002","spread":"211.99","value":"876.97"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"3"}],"units":"Participants"}],"title":"Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"242.96","value":"639.59"},{"groupId":"OG001","spread":"291.34","value":"628.07"},{"groupId":"OG002","value":"977.09"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"1"}],"units":"Participants"}],"title":"Day 15"}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"3"}],"units":"Participants"}],"dispersionType":"Standard Deviation","groups":[{"description":"Participants received Dose A intravenously (IV) on Days 1, 8, and 15 in each 28-day cycle. In addition, participants received a fixed dose of 25 mg oral lenalidomide on Days 1 through 21 and a fixed dose of 40 mg oral dexamethasone on Days 1, 8, 15, and 22 of each 28-day cycle.","id":"OG000","title":"CEP-18770 Dose A"},{"description":"Participants received CEP-18770 Dose B IV on Days 1, 8, and 15 in each 28-day cycle. In addition, participants received a fixed dose of 25 mg oral lenalidomide on Days 1 through 21 and a fixed dose of 40 mg oral dexamethasone on Days 1, 8, 15, and 22 of each 28-day cycle.","id":"OG001","title":"CEP-18770 Dose B"},{"description":"Participants received CEP-18770 Dose C IV on Days 1, 8, and 15 in each 28-day cycle. In addition, participants received a fixed dose of 25 mg oral lenalidomide on Days 1 through 21 and a fixed dose of 40 mg oral dexamethasone on Days 1, 8, 15, and 22 of each 28-day cycle.","id":"OG002","title":"CEP-18770 Dose C"}],"paramType":"MEAN","populationDescription":"The pharmacokinetic (PK) analysis set included all participants for whom at least 1 PK parameter can be calculated. Here, number analyzed = participants evaluable at specified timepoint.","reportingStatus":"POSTED","timeFrame":"Before and immediately after end of infusion (EOI) and at approximately 2, 4, and 8 hours after the EOI on Days 1 and 15 of Cycle 1","title":"Maximum Observed Plasma Concentration (Cmax) of CEP-18770","type":"SECONDARY","unitOfMeasure":"nanograms (ng)/ milliliter (mL)"}